Avantor (AVTR) vs Harvard Bioscience (HBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Harvard Bioscience (HBIO) has outperformed Avantor (AVTR) over the past year, gaining 93.2% versus a gain of 14.0%. Over five years, AVTR leads with a -60.0% price change compared with -87.6% for HBIO. Avantor is the larger company by market cap ($10.38 billion vs $38.7 million), about 268.3 times the size.
On valuation, Harvard Bioscience trades at a lower forward P/E (13.2x vs 17.5x for Avantor).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTR | HBIO |
|---|---|---|
| Share price | $15.35 | $8.50 |
| Market cap | $10.38B | $38.69M |
| 1-day change | -0.52% | -0.70% |
| YTD return | +33.94% | +26.87% |
| 1-year return | +13.96% | +93.18% |
| 5-year return | -59.97% | -87.57% |
| Forward P/E | 17.48 | 13.18 |
| EPS (TTM) | $-0.84 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.55B | — |
| Revenue growth (YoY) | -3.41% | — |
| Net income (latest FY) | $-530.20M | — |
| Gross margin | 32.65% | — |
| Operating margin | -3.76% | — |
| Net margin | -8.09% | — |
| 52-week high | $16.38 | $9.40 |
| 52-week low | $7.27 | $3.80 |
| Distance from 52-week high | -6.26% | -9.57% |
| Analyst consensus | hold | — |
| Avg. price target upside | -3.71% | — |
| Average volume | 9.45M | 18.02K |
| Shares outstanding | 676.36M | 4.55M |
| Employees | 13,500 | — |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Avantor is about 268.3 times larger than Harvard Bioscience by market value ($10.38B vs $38.69M).
- HBIO has outperformed AVTR by 79.2 percentage points over the past year.
About Avantor
AVTR stock →Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
Industrials · Biotechnology: Laboratory Analytical Instruments · 13,500 employees
AVTR vs HBIO FAQ
Which is bigger, Avantor or Harvard Bioscience?
Avantor (AVTR) is larger, with a market capitalization of $10.38B compared with $38.69M for Harvard Bioscience (HBIO).
Which stock has performed better over the past year, AVTR or HBIO?
HBIO returned +93.18% over the past 12 months, compared with +13.96% for AVTR (price return, excluding dividends). Past performance does not predict future results.
Are Avantor and Harvard Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.